# A ligand-centered framework for γδ T cell activation in colorectal cancer revealed by single-cell and transformer-based perturbation

**Authors:** Ran Ran, Douglas K. Brubaker

PMC · DOI: 10.3389/fimmu.2025.1715827 · 2026-01-13

## TL;DR

This study identifies key ligands and transcription factors involved in γδ T cell activation in colorectal cancer, offering insights for improved immunotherapies.

## Contribution

A novel ligand inference pipeline combining single-cell data and in silico perturbation to reveal γδ T cell activation mechanisms in CRC.

## Key findings

- IL-15 and TNFSF9 (4-1BBL) promote γδ T cell effector function.
- NCR2 and KLRC3 (NKG2E) are linked to γδ T cell activation when overexpressed.
- Monocytes and dendritic cells are key contributors to γδ T cell activation in the tumor microenvironment.

## Abstract

Understanding the activation mechanisms of γδ T cells in colorectal cancer (CRC) is critical for harnessing their therapeutic potential. Here, using an atlas of human CRC-infiltrating γδ T cells that we built by integrating multiple single-cell RNA-seq datasets, we developed a γδ T cell-refined ligand inference pipeline by combining differential gene expression, gene regulatory network prediction, ligand inference, and in silico perturbation analysis. This approach identified ligands, including IL-15 and TNFSF9 (4-1BBL), as candidates promoting γδ T cell effector function and highlighted NCR2 and KLRC3 (NKG2E), whose in silico overexpression was associated with γδ T cell activation. Ligand enrichment analyses further indicated that monocytes and dendritic cells are key contributors to γδ T cell activation in the tumor microenvironment. Our results also highlighted transcription factors IKZF1, FOSL2, and FOXO1 in the less activated γδ T cells and IRF1, KLF2, and BHLHE40 in the effector γδ T cells that plausibly regulated the differential activation state. Together, our results offer a systems-level view of the signaling and transcriptional programs governing γδ T cell phenotypes in CRC and provide a foundation for γδ T cell-based immunotherapies with enhanced antitumor functions.

## Linked entities

- **Genes:** IL15 (interleukin 15) [NCBI Gene 3600], TNFSF9 (TNF superfamily member 9) [NCBI Gene 8744], NCR2 (natural cytotoxicity triggering receptor 2) [NCBI Gene 9436], KLRC3 (killer cell lectin like receptor C3) [NCBI Gene 3823], IKZF1 (IKAROS family zinc finger 1) [NCBI Gene 10320], FOSL2 (FOS like 2, AP-1 transcription factor subunit) [NCBI Gene 2355], FOXO1 (forkhead box O1) [NCBI Gene 2308], IRF1 (interferon regulatory factor 1) [NCBI Gene 3659], KLF2 (KLF transcription factor 2) [NCBI Gene 10365], BHLHE40 (basic helix-loop-helix family member e40) [NCBI Gene 8553]
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** FOSL2 (FOS like 2, AP-1 transcription factor subunit) [NCBI Gene 2355] {aka ACED, FRA2}, NCR2 (natural cytotoxicity triggering receptor 2) [NCBI Gene 9436] {aka CD336, LY95, NK-p44, NKP44, dJ149M18.1}, TNFSF9 (TNF superfamily member 9) [NCBI Gene 8744] {aka 4-1BB-L, CD137L, TNLG5A}, IRF1 (interferon regulatory factor 1) [NCBI Gene 3659] {aka IMD117, IRF-1, MAR}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, KLF2 (KLF transcription factor 2) [NCBI Gene 10365] {aka LKLF}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, IKZF1 (IKAROS family zinc finger 1) [NCBI Gene 10320] {aka CVID13, Hs.54452, IK1, IKAROS, LYF1, LyF-1}, KLRC3 (killer cell lectin like receptor C3) [NCBI Gene 3823] {aka NKG2-E, NKG2E}, BHLHE40 (basic helix-loop-helix family member e40) [NCBI Gene 8553] {aka BHLHB2, Clast5, DEC1, HLHB2, SHARP-2, SHARP2}
- **Diseases:** gammadelta T (MESH:D001260), CRC (MESH:D015179), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12835328/full.md

---
Source: https://tomesphere.com/paper/PMC12835328